NorthMiRs is developing nanotechnology-enabled gene therapies for the treatment of sepsis. We have determined microRNAs that are dysregulated in septic patients and packaged them into a stable, synthetic, and scalable lipid nanoparticle delivery vehicle. Our lead therapeutic, NM-001, a miRNA replacement therapy for sepsis-associated cardiomyopathy has been shown to be anti-inflammatory, anti-microbial and protects organs […]
Read More